Read our review of some of the biggest FDA-related stories that have hit cardiology in the last month, including news from Viz.ai, Edwards Lifesciences, Abiomed and Medtronic. 

Dozens of medical societies have signed a new letter urging Congress to stop upcoming Medicare payment cuts. “The Medicare payment system remains on an unsustainable path threatening beneficiaries’ access to physicians," they wrote. 

Shockwave announced at TCT 2022 that it hopes to enroll up to 400 patients for a new all-female clinical trial.

Researchers examined data from nearly 5,400 patients, tracking such outcomes as myocardial infarction, stroke and all-cause mortality. 

When these malfunctions occur, the FDA explained, it leads to an increased risk of additional interventions.

The new study, based on data from nearly 3,000 patients, compared DOACs such as rivaroxaban, apixaban and edoxaban with single and dual antiplatelet therapy. 

Check out this week’s Movers & Shakers from Health Exec, a roundup of the latest executive movements in the healthcare industry.

Researchers found that cancer risk in premenopausal women with fatty breasts at initial imaging nearly doubled if an increase in density was observed during their second and third mammograms.